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The challenge of progressive MS therapy 
 
Abstract 
Purpose of review 
Understanding the mechanisms underlying progression in multiple sclerosis (MS) 
and identifying appropriate therapeutic targets is a key challenge facing the MS 
community. This challenge has been championed internationally by organisations 
such as the Progressive MS Alliance, which has raised the profile of progressive MS 
and identified the key obstacles to treatment. This review will outline the 
considerable progress against these challenges.  
Recent findings 
New insights into mechanisms underlying progression have opened up potential 
therapeutic opportunities. This has been complemented by ongoing validation of 
clinical and imaging outcomes for Phase II trials of progression, coupled with the 
development of innovative trial designs. The field has been greatly encouraged by 
recent positive Phase III trials in both primary and secondary progressive multiple 
sclerosis, albeit with modest benefit. Early trials of neuroprotection and repair have 
provided important new data with which to drive the field. Improving symptom 
management and advancing rehabilitation approaches, critical for this patient 
population which, taken together with identifying and managing co-morbidities and 
risk factors, has an appreciable impact on health-related quality of life.   
Summary   
 Raising the profile of progressive MS has resulted in the first effective treatments 
with the promise of more to come.   
Introduction 
The challenge of finding treatments for and improving the management of 
progressive multiple sclerosis subsumes a number of fundamental issues, outlined in 
a publication from the International Progressive Multiple Sclerosis Alliance (PMSA)1. 
They include (i) understanding the mechanisms underlying progression and 
identifying potential targets (ii) appropriate trial design and outcome measures (iii) 
improving symptomatic treatment and rehabilitation.    
The recent exploration of the MS phenotype and, in particular, comparison of the two 
progressive forms of MS has been helpful in that it acknowledges the consensus that 
while there are some differences between those that are progressive from onset 
(primary progressive) and those that develop progression after a period of relapses 
and remissions (secondary progressive); these differences are relative rather than 
absolute. This is not to dismiss the primary progressive phenotype which is 
considered by many to be the ideal model with which to study progression. An 
interesting paper by Kantarci and colleagues2 - followed a cohort of 453 subjects 
with so-called radiologically-isolated syndromes (RIS), studied in 22 clinical sites. 
During a 15-year follow-up, 128 patients evolved to symptomatic MS and 15 of those 
developed PPMS with a median time to conversion of 3.5 years, demonstrating that 
subjects with RIS evolve to PPMS in the same frequency as would be expected in 
general MS populations. The strongest predictors of evolution of PPMS included 
male gender, more advanced age, and the initial presence of asymptomatic spinal 
cord lesions. This frequency is however challenged by a recent Scandinavian study 
which suggests that the incidence of PPMS is reducing, falling from 19.2% to 2.2% 
over 30 years, a finding which needs verification in other populations3. The clinical 
definition of secondary progressive has also been quite challenging as it is invariably 
done retrospectively and tends to be further delayed because of impact on 
therapeutic options. The MSBase cohort study group worked through a bewildering 
number of options before reaching a definition which included the absence of a 
relapse, confirmed at three months, a score on the Expanded Disability Scale 
greater or equal to 4 and a pyramidal score greater or equal to 24. 
Mechanisms underpinning progression 
The fundamental issue in identifying treatments for progressive MS is a better 
understanding of the pathological mechanisms underlying progression, without which 
targets which are critical to that process cannot be identified with certainty5. This was 
the focus of a workshop which combined basic neuroscientists and clinicians which 
emphasised the urgent need to identify new therapeutic targets6. While the role of 
some players such as microglia, mitochondria and the innate immune system has 
been emphasised recently, the precise part they play is yet to be confirmed. A recent 
review explored potential mechanisms leading to secondary progression discussing 
a range of mechanisms, including aging, cumulative inflammatory injury exhausting 
resources and distinct intrinsic mechanisms7. An intriguing study utilising induced 
pluripotent stem (iPS) cells, has suggested a defect in myelin injury response in 
PPMs, which could help explain the nature of progression8. While, more recently, an 
interesting study has highlighted the potential role of the kynurenine pathway in the 
development of progression, possibly through interaction with quinolinic acid 
produced by activated microglia and implicated in excitotoxic neurodegeneration9 
In addition, several papers have attempted to clarify the pathological processes 
underpinning MS which have direct implications for progression. The first describes a 
simplified classification of lesions10 and the second provides a description of the 
topography of demyelination and neurodegeneration in MS and outlines two different 
patterns of neurodegeneration relating to oxidative injury and retrograde 
neurodegeneration11.   
Mechanisms underlying progression can also be studied utilising magnetic 
resonance imaging (MRI). A recent study paper has explored the temporal 
relationship between white and grey matter damage in early PPMS by applying both 
conventional and magnetization transfer imaging to specific cortical areas and their 
connected tracts12.  Results suggested that in the main, cortical damage is a 
sequelae of normal-appearing white matter pathology which in turn is determined by 
abnormalities within white matter lesions.  
Trial design and outcomes 
Moving from mechanisms, the next major challenge is around the practicalities of 
clinical trials and particularly the optimal trial design to evaluate an effect on 
progression and the ideal outcome measure to incorporate into such a trial, both at 
Phase II and Phase III level. Outcomes should include a clinical measure and a 
biomarker reflecting the underlying pathology and both pose challenges in 
progressive MS. Clinical evaluation continues to depend on the less than satisfactory 
Expanded Disability Status Scale. Biomarkers fall heavily towards MRI though work 
continues on CSF markers, notably neurofilaments and a recent paper has 
suggested that they may have a predictive role in the development of atrophy in 
progressive MS13. Atrophy is the favoured imaging measure and has been used in a 
number of recent studies including the Phase II trial of simvastatin in progressive 
MS14. Efforts are tending to focus on regional atrophy, particularly deep grey matter 
and also on the spinal cord which may be particularly sensitive in trials of PPMS. 
Finally biomarkers reflecting abnormalities of the visual pathway are becoming more 
prominent, most notably optical coherence tomography, a non-invasive technique 
which provides high resolution quantification of the retinal nerve fibre layer, and 
directly reflects axonal integrity of the optic nerves and correlates with clinical 
disability15. 
Clinical trials in progressive MS 
The last year has seen the publication of a number of clinical trials in progressive MS 
and while some have been disappointingly negative, most recently we have seen a 
positive trial in PPMS. The trial of fingolimod, an oral sphingosine 1-phosphate 
modulator receptor, which it was thought might have neuroprotective effects, was 
carried out in primary progressive MS, following the successful trial in the relapsing 
remitting cohort16.  A three year study of 970 patients utilising a novel primary 
outcome which was a composite of the EDSS, 25 foot timed-walk test and the nine-
hole peg test. The trial showed no difference between the treatment and placebo 
arms on any of the outcomes measured. An innovative trial of the co-factor Biotin 
involving 154 patients with secondary progressive MS was also published17. The 
proposed modes of action include supporting myelin repair and protecting against 
hypoxia-driven axonal degeneration (by enhancing energy production). The primary 
end point was unusual – the proportion of patients with disability reversal at month 9 
confirmed at month 12. The study was positive and Phase III trials are planned. A 
Phase III trial of simvastatin in secondary progressive MS will commence later in 
2017 – following on from the positive Phase II study12. Finally, and most 
encouragingly, a Phase III trial of Ocrelizumab, a humanised monoclonal antibody, 
related to rituximab, that selectively depletes CD-20 expressing B cells, was 
successful in primary progressive MS18. The trial included 732 patients and showed 
a 24% effect on the primary outcome - 12 week confirmed disability progression. 
Although relatively modest, this effect is a milestone in the therapeutics of 
progressive MS, reminiscent of the first positive trials of beta interferon in 
relapsing/remitting MS. 
Perhaps as encouraging, is the focus on neuroprotection for progressive MS. A 
study by Raftopolous et al19 has demonstrated that neuroprotection may be an 
important way forward. The study was carried out in an acute model - optic neuritis, 
applying phenytoin and demonstrated a positive effect. Currently there are two 
neuroprotective studies under way, both of which have been fully recruited. The first, 
SPRINT-MS, a trial of the neuroprotective agent ibudilast involves 155 patients with 
progressive MS20. The primary end point is change in whole brain atrophy as 
measured by parenchymal brain fraction over 96 weeks. There is also a range of 
advanced imaging measures. The second study, MS-SMART, has utilised an 
adaptive trial design to evaluate three neuroprotective agents – amiloride, riluzole 
and fluoxetine in secondary progressive MS21. 
Risk factors, symptomatic management, rehabilitation and co-morbidities 
Finally, optimum management of progressive MS includes a range of approaches, 
beyond potential pharmacological interventions to modify disease course, including 
(i) the identification of risk factors which worsen disability, (ii) symptomatic 
management and rehabilitation and (iii) the management of co-morbidities. 
Identifying and (iv) quantifying the role of risk factors with potential to modify the 
evolution of the progressive phase. This latter point is of paramount importance for 
patients and clinicians and while many factors are frequently cited as having an 
impact on disease course, surprisingly few have the necessary evidence-base to 
support this contention. A recent systematic review focused on fourteen risk factors 
and found that there was sufficient evidence to make definitive statements about 
only three of them; Lower Vitamin D levels were associated with higher EDSS scores 
and cigarette smokers had an increased risk of progression while there was no 
evidence of an association between disease progression and the use of epidural 
analgesics during childbirth22. For the other eleven risk factors, which included diet, 
alcohol, exercise and trauma there was insufficient evidence to determine a 
compelling relationship with progression. In their companion paper, 37 trials of the 
effect of modifiable risk factor interventions on progression were reviewed and no 
clear beneficial effect from any risk factor was identified23. The evidence base for 
rehabilitation and symptomatic management in progressive MS is also quite 
limited24. However a recent systematic review of physiotherapy in this population 
suggested some efficacy though there was a major concern around methodology25. 
A recently acknowledged area which has a major impact on MS and perhaps 
particularly on the progressive MS population, is the issue of co-morbidities26. Two 
recent papers which emanated from an international workshop clarify the prevalence 
of key co-morbidities in MS27 and, importantly, determine how they should be 
incorporated into clinical trials both in terms of safety and efficacy of the intervention 
under study28. 
 
 
Conclusion 
Activity within the progressive space has increased dramatically and the profile of 
progressive MS has risen substantially. The blocks to treatment are being actively 
addressed and we have the first effective agent in primary progressive MS. These 
advances give cause for optimism but shouldn’t be allowed to slow the momentum 
towards more effective treatments which strike at the very heart of the mechanisms 
underpinning progression.  
 
 
Bullet points 
 Developing effective treatments for Progressive MS is one of the key 
challenges for the MS community 
 Understanding the mechanisms underpinning progression is fundamental to 
the identification of drugable targets 
 Progress is being made in the development of appropriate trial design and 
outcome measure releavent to progression 
 We now have the first effective treatment for primary progressive MS 
 Increased focus on modifiable risk factors, symptom management, 
rehabilitation and co-morbidies will improve health-related quality of life for 
people with progressive MS 
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